- Home
- CODX vs CMMB Comparison
CODX vs CMMB Comparison
Compare CODX & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CODX
- CMMB
- Stock Information
- Founded
- CODX 2013
- CMMB 2004
- Country
- CODX United States
- CMMB Israel
- Employees
- CODX N/A
- CMMB N/A
- Industry
- CODX Medical/Dental Instruments
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- CODX Health Care
- CMMB Health Care
- Exchange
- CODX Nasdaq
- CMMB Nasdaq
- Market Cap
- CODX 16.9M
- CMMB 13.7M
- IPO Year
- CODX 2017
- CMMB N/A
- Fundamental
- Price
- CODX $0.39
- CMMB $3.50
- Analyst Decision
- CODX Buy
- CMMB Strong Buy
- Analyst Count
- CODX 2
- CMMB 2
- Target Price
- CODX $2.00
- CMMB $26.50
- AVG Volume (30 Days)
- CODX 14.5M
- CMMB 214.4K
- Earning Date
- CODX 11-06-2025
- CMMB 11-13-2025
- Dividend Yield
- CODX N/A
- CMMB N/A
- EPS Growth
- CODX N/A
- CMMB N/A
- EPS
- CODX N/A
- CMMB N/A
- Revenue
- CODX $1,003,653.00
- CMMB N/A
- Revenue This Year
- CODX N/A
- CMMB N/A
- Revenue Next Year
- CODX $31.58
- CMMB N/A
- P/E Ratio
- CODX N/A
- CMMB N/A
- Revenue Growth
- CODX N/A
- CMMB N/A
- 52 Week Low
- CODX $0.23
- CMMB $2.39
- 52 Week High
- CODX $1.40
- CMMB $9.84
- Technical
- Relative Strength Index (RSI)
- CODX 48.59
- CMMB 76.10
- Support Level
- CODX $0.32
- CMMB $2.60
- Resistance Level
- CODX $0.41
- CMMB $2.79
- Average True Range (ATR)
- CODX 0.04
- CMMB 0.16
- MACD
- CODX -0.01
- CMMB 0.02
- Stochastic Oscillator
- CODX 28.99
- CMMB 90.50
About CODX Co-Diagnostics Inc.
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.